Chung, V., Guthrie, K. A., Pishvaian, M. J., Lowy, A. M., Sohal, D., Colby, S., Reiss, K. A., Khan, G., Winograd, R., Meyerhardt, J. A., O'Reilly, E. M., Chiorean, E. G., Philip, P. A. (2026). Randomized phase II trial of olaparib and pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2) mutations: SWOG S2001.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4012